AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense

Key Takeaways ABBV shares fell 3.2% in a month after it denied reports of talks to acquire Revolution Medicines.ABBV is offsetting Humira LOE as Skyrizi & Rinvoq delivered $18.5B in sales in the first nine months of 2025.ABBV faces Aesthetics weakness and Humira erosion, but oncology and neuroscience growth lift revenues.AbbVie (ABBV) stock has declined 3.2% in a month. Shares of this large drugmaker dipped recently after it denied takeover talks with Redwood City, CA-based cancer biotech, Revolution Medici ...